We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CDC to Healthcare Facilities: Review Your Reprocessing Practices

CDC to Healthcare Facilities: Review Your Reprocessing Practices

September 18, 2015

Citing recent reports of infection control lapses, the FDA and Centers for Disease Control and Prevention are advising healthcare facilities to ensure they are complying with device manufacturers’ instructions for reprocessing reusable devices.

In a health advisory, the agencies recommend that healthcare facilities work with an expert to ensure correct device reprocessing procedures. Facilities also should train all personnel involved in reprocessing at the time they are hired or before they provide services at the facility. Personnel must show competency before performing procedures independently.

Further, employees should receive updated training at least once a year and when new devices or protocols are introduced.

The agencies also advise facilities to monitor and document adherence to cleaning, disinfection, sterilization and device storage procedures. Protocols should ensure employees can easily identify devices that have been properly reprocessed and are ready for patient use.

The advisory comes after reports of notifications, warning patients that they may be at increased risk as a result of inadequate cleaning, disinfection and sterilization of medical devices.

Earlier this year, the FDA said that between January 2013 and December 2014, it received reports involving about 135 patients infected with carbapenem-resistant Enterobacteriaceae after they were examined with a complex type of endoscope known as a duodenoscope. Antibiotic-resistant infections were reported in Chicago, Pittsburgh, Seattle and Los Angeles.

The FDA has sought to ensure adequate reprocessing, issuing final guidance strengthening controls on reprocessing in March (IDDM, March 13). It also provided new guidelines to help healthcare facilities in cleaning their duodenoscopes (IDDM, Aug. 7).

The advisory is available at www.fdanews.com/092115-CDC-advisory.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing